Sara Karlovitch | Authors


GlaxoSmithKline Discontinues Feladilimab in Clinical Trials for Metastatic HNSCC

April 16, 2021

GlaxoSmithKline plc has announced that they will stop enrolling patients in the phase 2 INDUCE-3 and INDUCE-4 trials while simultaneously ending the use of feladilimab, originally GSK3359609, for the treatment of PD-L1-positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma after the recommendation of the Independent Data Monitoring Committee.